AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28558781 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention including sit-stand workstation, individual health coaching, and organisational support strategies
Number of subjects: 28
Study 28558781 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand workstations
Number of subjects: 28
Study 28558781 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from team leaders and other participants
Number of subjects: 28
Study 26007710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan
Number of subjects: 8
Study 26007710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 22763027 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (CRT)
Number of subjects: 222
Study 21167347 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 1504
Study 21167347 — intervention group
Group type: COMPARATOR
Intervention: Continuing smoking
Number of subjects: 1504
Study 18164990 — intervention group
Group type: EXPERIMENTAL
Intervention: FF 55 microg
Number of subjects: 558
Study 18164990 — intervention group
Group type: EXPERIMENTAL
Intervention: FF 110 microg
Number of subjects: 558
Study 18164990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 558
Study 17186736 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingling Dingxuan Decoction (QDD)
Number of subjects: 39
Study 17186736 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine
Number of subjects: 39
Study 12540791 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Number of subjects: 165
Study 12540791 — intervention group
Group type: EXPERIMENTAL
Intervention: Right heart catheterization
Number of subjects: 165
Study 12540791 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial phase of transplantation
Number of subjects: 165
Study 12540791 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting for a graft
Number of subjects: 165
Study 10692616 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic NSAID use (>/=2 months)
Number of subjects: 19364
Study 10692616 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to NSAIDs)
Number of subjects: 19364
Study 8982891 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-nitrous oxide
Number of subjects: 50
Study 8982891 — intervention group
Group type: COMPARATOR
Intervention: Propofol-nitrous oxide
Number of subjects: 50
Study 1595998 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg loading dose over 20 min, followed by 0.9 mg/kg/h maintenance infusion)
Number of subjects: 9
Study 1595998 — intervention group
Group type: COMPARATOR
Intervention: Oxygen (100% O2 breathing)
Number of subjects: 9
Study 6372707 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg artificial surfactant in 1 ml saline
Number of subjects: 12
Study 6372707 — intervention group
Group type: COMPARATOR
Intervention: Saline only
Number of subjects: 12
Study 29727330 — intervention group
Group type: EXPERIMENTAL
Intervention: Side‐by‐side unregistered image guidance (IG)
Number of subjects: 36
Study 29727330 — intervention group
Group type: COMPARATOR
Intervention: No guidance control (NG)
Number of subjects: 36
Study 29727330 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfect augmented reality (AR)
Number of subjects: 36
Study 30138795 — intervention group
Group type: EXPERIMENTAL
Intervention: COP (copulation)
Number of subjects: 24
Study 30138795 — intervention group
Group type: COMPARATOR
Intervention: CON (control)
Number of subjects: 24
Study 27273433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Number of subjects: 1091
Study 27273433 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1091
Study 25127011 — intervention group
Group type: COMPARATOR
Intervention: Alendronate discontinuation (placebo)
Number of subjects: 404
Study 22325683 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-hour arm crank ergometer exercise at 60% maximum oxygen consumption
Number of subjects: 16
Study 20103076 — intervention group
Group type: EXPERIMENTAL
Intervention: FLS proficiency‐based curriculum training (n = 9)
Number of subjects: 19
Study 20103076 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 19
Study 18358540 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 200 mg/day over 8 weeks
Number of subjects: 72
Study 18358540 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (Li) at least 900 mg/day over 2 weeks (serum level 0.6-1.2 mEq/L)
Number of subjects: 72
Study 18358540 — intervention group
Group type: COMPARATOR
Intervention: Lithium (Li)
Number of subjects: 72
Study 15972272 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet
Number of subjects: 10
Study 15972272 — intervention group
Group type: COMPARATOR
Intervention: 4-day complete fast
Number of subjects: 10
Study 11835029 — intervention group
Group type: EXPERIMENTAL
Intervention: ST recovery <30% in the single lead with maximum ST elevation
Number of subjects: 766
Study 11835029 — intervention group
Group type: EXPERIMENTAL
Intervention: ST recovery 30% to 70% in the single lead with maximum ST elevation
Number of subjects: 766
Study 11835029 — intervention group
Group type: EXPERIMENTAL
Intervention: ST recovery >70% in the single lead with maximum ST elevation
Number of subjects: 766
Study 11835029 — intervention group
Group type: EXPERIMENTAL
Intervention: ST recovery >70% in patients with TIMI grade 3 flow
Number of subjects: 766
Study 11835029 — intervention group
Group type: EXPERIMENTAL
Intervention: ST recovery measured as the sum of voltage changes of either ST deviation or ST elevation
Number of subjects: 766
Study 11835029 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, ST recovery (continuous variable), diabetes, female gender
Number of subjects: 766
Study 11835029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction and TIMI flow grade at 3 weeks
Number of subjects: 766
Study 10079449 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mm capsulorhexis
Number of subjects: 58
Study 10079449 — intervention group
Group type: COMPARATOR
Intervention: 6.0 mm capsulorhexis
Number of subjects: 58
Study 10079449 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 4.0 mm and 6.0 mm capsulorhexis
Number of subjects: 58
Study 7673534 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 176
Study 7673534 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy (IT)
Number of subjects: 176
Study 1710009 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (Trasylol) high dosage (about 800 mg) during extracorporeal circulation
Number of subjects: 22
Study 1710009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 22
Study 7224261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin (250 mg orally q.i.d. x 5 days)
Number of subjects: 394
Study 7224261 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (control group)
Number of subjects: 394
Study 31477783 — intervention group
Group type: EXPERIMENTAL
Intervention: General sleep and activity guidelines
Number of subjects: 547
Study 31477783 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity intensity (60 min of energetic play) and sleep regularity (consistent sleep and wake times)
Number of subjects: 547
Study 31477783 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting all three guidelines at a given age
Number of subjects: 547
Study 31477783 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to all three guidelines at earlier ages
Number of subjects: 547
Study 28931929 — intervention group
Group type: EXPERIMENTAL
Intervention: 9602 A. cristatum expressed sequence tag-sequence-tagged site (EST-STS) markers for PCR amplification and experimental screening; 6063 polymorphic EST-STS markers specific for the A. cristatum P genome in the single-receipt wheat background.
Number of subjects: 0
Study 25501100 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB with BMC treatment
Number of subjects: 90
Study 25501100 — intervention group
Group type: COMPARATOR
Intervention: OPCAB with saline (control)
Number of subjects: 90
Study 23510529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10-20 mg/day) plus vitamin C (1000 mg/day)
Number of subjects: 12
Study 23510529 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (10-20 mg/day) plus placebo
Number of subjects: 12
Study 21608221 — intervention group
Group type: EXPERIMENTAL
Intervention: Huazhuo Jiedu Recipe (HJR)
Number of subjects: 229
Study 21608221 — intervention group
Group type: COMPARATOR
Intervention: Weifuchun Tablet (Control)
Number of subjects: 229
Study 19849835 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedded motor imagery training
Number of subjects: 0
Study 19849835 — intervention group
Group type: EXPERIMENTAL
Intervention: Added motor imagery training
Number of subjects: 0
Study 19849835 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy intervention (Control Group)
Number of subjects: 0
Study 16573982 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-skills training (Cohort 2 and Cohort 3)
Number of subjects: 295
Study 16573982 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-skills training (Cohort 3)
Number of subjects: 295
Study 16573982 — intervention group
Group type: COMPARATOR
Intervention: No preparation (Cohort 1)
Number of subjects: 295
Study 15017515 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid 1.0 g 3 times a day
Number of subjects: 321
Study 15017515 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid 0.5 g 3 times a day
Number of subjects: 321
Study 15017515 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid 1.5 g 3 times a day
Number of subjects: 321
Study 15017515 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (all doses)
Number of subjects: 321
Study 10673129 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Drinking Test (WDT)
Number of subjects: 36
Study 9066215 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam adhesive as the principal mode of retention
Number of subjects: 0
Study 9066215 — intervention group
Group type: COMPARATOR
Intervention: Traditional pin-retained amalgams
Number of subjects: 0
Study 8346133 — intervention group
Group type: EXPERIMENTAL
Intervention: 201-thallium/99m-technetium subtraction scanning (Tl/Tc)
Number of subjects: 25
Study 8346133 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 MHz ultrasound
Number of subjects: 25
Study 8346133 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (Tl/Tc and ultrasound)
Number of subjects: 25
Study 8346133 — intervention group
Group type: COMPARATOR
Intervention: Tl/Tc scanning
Number of subjects: 25
Study 8346133 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 25
Study 8346133 — intervention group
Group type: COMPARATOR
Intervention: Both techniques together
Number of subjects: 25
Study 3554818 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 to 20 mg/d)
Number of subjects: 20
Study 3554818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30274655 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus healthy lifestyle instruction
Number of subjects: 61
Study 30274655 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle instruction alone
Number of subjects: 61
Study 26108445 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical combination therapy with maxacalcitol ointment and betamethasone butyrate propionate ointment (BBP)
Number of subjects: 27
Study 26108445 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid (BBP) alone
Number of subjects: 27
Study 25187436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium- and fluid-restricted diet (0.8 g/day sodium and 800 mL/day fluid)
Number of subjects: 0
Study 25187436 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet (4 g/day sodium and unlimited fluid intake)
Number of subjects: 0
Study 24097171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion at 15 °C (C15)
Number of subjects: 9
Study 24097171 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast water therapy (CT)
Number of subjects: 9
Study 24097171 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral water immersion at 34 °C (T34)
Number of subjects: 9
Study 24097171 — intervention group
Group type: COMPARATOR
Intervention: Cycling at 40% peak (AR)
Number of subjects: 9
Study 20534765 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 25 mg
Number of subjects: 103
Study 20534765 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 50 mg
Number of subjects: 103
Study 20534765 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 125 mg
Number of subjects: 103
Study 20534765 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 300 mg
Number of subjects: 103
Study 20534765 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 600 mg
Number of subjects: 103
Study 20534765 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 103
Study 18404076 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous beta-blocker (BB)
Number of subjects: 42
Study 18404076 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 42
Study 16511414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 259
Study 15217715 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (in a double-blind, placebo-controlled, randomized clinical trial)
Number of subjects: 1630
Study 15217715 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 1630
Study 15217715 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 1630
Study 11517126 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil
Number of subjects: 0
Study 11517126 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/remifentanil
Number of subjects: 0
Study 11517126 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil and Sevoflurane/remifentanil
Number of subjects: 0
Study 9768937 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 100
Study 9768937 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional ultrafiltration)
Number of subjects: 100
Study 7810251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (500 mg intravenous infusion within 3 h after trauma, followed by 200 mg after 3 h, then 8 times 200 mg at 6 hourly intervals, total dose 2.3 g in 51 hours)
Number of subjects: 300
Study 7810251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 3292634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed challenge
Number of subjects: 18
Study 3292634 — intervention group
Group type: COMPARATOR
Intervention: Unchallenged blisters from allergic and nonallergic patients
Number of subjects: 18
Study 3292634 — intervention group
Group type: COMPARATOR
Intervention: Ragweed challenge in nonallergic patients
Number of subjects: 18
Study 3292634 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PGD2 levels
Number of subjects: 18
Study 29856103 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 60
Study 29856103 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 60
Study 29856103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29856103 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 28742911 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM for 48 hours (n=176)
Number of subjects: 355
Study 28742911 — intervention group
Group type: COMPARATOR
Intervention: TTM for 24 hours (n=179)
Number of subjects: 355
Study 28742911 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM for 48 hours
Number of subjects: 355
Study 28742911 — intervention group
Group type: COMPARATOR
Intervention: TTM for 24 hours
Number of subjects: 355
Study 26285766 — intervention group
Group type: EXPERIMENTAL
Intervention: Iniparib with monthly temozolomide (mTMZ) dosing (150‐200 mg/m(2) days 1‐5/28 days)
Number of subjects: 43
Study 26285766 — intervention group
Group type: EXPERIMENTAL
Intervention: Iniparib with continuous temozolomide (cTMZ) dosing (75 mg/m(2)/days × 6 weeks)
Number of subjects: 43
Study 26285766 — intervention group
Group type: EXPERIMENTAL
Intervention: Iniparib
Number of subjects: 43
Study 26285766 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended phase 2 dosing of iniparib
Number of subjects: 43
Study 26285766 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy study of TMZ/RT + iniparib followed by TMZ + iniparib
Number of subjects: 43
Study 25154147 — intervention group
Group type: EXPERIMENTAL
Intervention: Two small incision technique
Number of subjects: 56
Study 25154147 — intervention group
Group type: COMPARATOR
Intervention: Single long midline incision technique
Number of subjects: 56
Study 21397316 — intervention group
Group type: EXPERIMENTAL
Intervention: Solobond M + Grandio
Number of subjects: 30
Study 21397316 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac + Tetric Ceram
Number of subjects: 30
Study 21397316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 30
Study 18707846 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3mg/kg) at weeks 0, 2, 6 and 14
Number of subjects: 20
Study 18707846 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3mg/kg) administered at baseline
Number of subjects: 20
Study 16939405 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level whole body vibration (30 Hz, 0.3g) for 10 minutes daily for 12 months
Number of subjects: 48
Study 16939405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 16939405 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level whole body vibration (30 Hz, 0.3g) for 10 minutes daily for 12 months (per protocol analysis)
Number of subjects: 48
Study 14510790 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild laser treatment using an argon green laser
Number of subjects: 38
Study 14510790 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 38
Study 11376359 — intervention group
Group type: EXPERIMENTAL
Intervention: Brewer's yeast (23.3ug Cr/day)
Number of subjects: 78
Study 11376359 — intervention group
Group type: EXPERIMENTAL
Intervention: CrCl3 (200ug Cr/day)
Number of subjects: 78
Study 11376359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 9108387 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IL-10 (rhIL-10; 25 microg/kg) pre-treatment
Number of subjects: 16
Study 9108387 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IL-10 (rhIL-10; 25 microg/kg) post-treatment
Number of subjects: 16
Study 9108387 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 9108387 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IL-10 (rhIL-10; 25 microg/kg) pre-treatment and post-treatment
Number of subjects: 16
Study 8211871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised amiloride
Number of subjects: 24
Study 8211871 — intervention group
Group type: COMPARATOR
Intervention: Nebulised saline (placebo)
Number of subjects: 24
Study 8211871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal potential difference measurement after amiloride
Number of subjects: 24
Study 8211871 — intervention group
Group type: COMPARATOR
Intervention: Nasal potential difference measurement after saline
Number of subjects: 24
Study 3530773 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 50
Study 3530773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29459150 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1 cartridge of 4% prilocaine plain plus 1 cartridge of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 118
Study 29459150 — intervention group
Group type: COMPARATOR
Intervention: Combination of 2 cartridges of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 118
Study 29459150 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 4% prilocaine plain plus 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 118
Study 27137970 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Buddy (HB) - telehealth monitoring intervention
Number of subjects: 25
Study 27137970 — intervention group
Group type: COMPARATOR
Intervention: Intensive Case Monitoring (ICM) alone
Number of subjects: 25
Study 25204100 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with ACoA syndrome
Number of subjects: 110
Study 25204100 — intervention group
Group type: COMPARATOR
Intervention: Women without parental alcoholism in childhood (control group)
Number of subjects: 110
Study 23131288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) treatment, 200 kU every 8 hours
Number of subjects: 60
Study 23131288 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 60
Study 20367218 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g/day palatinose-blended sugar (PS group)
Number of subjects: 50
Study 20367218 — intervention group
Group type: COMPARATOR
Intervention: 40 g/day sucrose (S group)
Number of subjects: 50
Study 18501139 — intervention group
Group type: EXPERIMENTAL
Intervention: AM3
Number of subjects: 253
Study 15983450 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% inspired oxygen in air plus intravenous administration of saline
Number of subjects: 210
Study 15983450 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% inspired oxygen in air plus intravenous administration of saline
Number of subjects: 210
Study 15983450 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% inspired oxygen in air plus 75 microg/kg ondansetron intravenously
Number of subjects: 210
Study 12667024 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1715
Study 12667024 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 1715
Study 12667024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1715